Pharma Mar (PHMMF) Projected to Announce Quarterly Earnings on Wednesday

Pharma Mar (OTCMKTS:PHMMF) will likely be announcing its resultson Wednesday, July 29th. Analysts expect Pharma Mar to announce earnings of $0.2027 per share and revenue of $50.4790 million for the quarter.

Pharma Mar Stock Performance

Shares of Pharma Mar stock opened at $86.09 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.44 and a current ratio of 3.02. Pharma Mar has a 52-week low of $77.41 and a 52-week high of $110.40. The company’s 50 day moving average price is $93.21 and its 200-day moving average price is $93.90.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. BTIG Research initiated coverage on shares of Pharma Mar in a research report on Thursday, April 23rd. They set a “buy” rating for the company. Zacks Research raised shares of Pharma Mar to a “hold” rating in a research note on Monday, June 15th. Finally, Chardan Capital upgraded shares of Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Pharma Mar presently has an average rating of “Buy”.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.